Pragmatic trials - Revision history

Lawrence: /* Bibliography */

2025-06-04T13:22:00Z

Bibliography

← Older revision		Revision as of 13:22, 4 June 2025
Line 43:		Line 43:
	Pragmatic RCTs bridge the gap between research and practice by emphasizing external validity and real-world applicability. By reflecting the complexities of routine healthcare delivery, pRCTs generate evidence that is both actionable and relevant to patients, providers, and policymakers. As healthcare systems seek to adopt interventions that are both effective and scalable, pRCTs will continue to play a pivotal role in guiding the future of evidence-based medicine.		Pragmatic RCTs bridge the gap between research and practice by emphasizing external validity and real-world applicability. By reflecting the complexities of routine healthcare delivery, pRCTs generate evidence that is both actionable and relevant to patients, providers, and policymakers. As healthcare systems seek to adopt interventions that are both effective and scalable, pRCTs will continue to play a pivotal role in guiding the future of evidence-based medicine.

	~~===Bibliography===~~


			=== Bibliography ===

			# Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the [[CONSORT]] statement. ''BMJ''. 2008;337:a2390.
			# Ford I, Norrie J. Pragmatic trials. ''New England Journal of Medicine''. 2016;375(5):454–463.
			# Patsopoulos NA. A pragmatic view on pragmatic trials. ''Dialogues in Clinical Neuroscience''. 2011;13(2):217–224.
			# Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. ''BMJ''. 2015;350:h2147.
			# Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers. ''CMAJ''. 2009;180(10):E47–E57.
	# Thabane L, Kaczorowski J, Dolovich L, Chambers LW, Mbuagbaw L. Reducing the confusion and controversies around pragmatic trials: using the Cardiovascular Health Awareness Program (CHAP) trial as an illustrative example. Trials. 2015;16(1):387.		# Thabane L, Kaczorowski J, Dolovich L, Chambers LW, Mbuagbaw L. Reducing the confusion and controversies around pragmatic trials: using the Cardiovascular Health Awareness Program (CHAP) trial as an illustrative example. Trials. 2015;16(1):387.
	~~# Sackett DL. Clinician-trialist rounds: 16. Mind your explanatory and pragmatic attitudes! - part 1:what? Clin Trials. 2013;10(3):495-498.~~
	~~# Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the [[CONSORT]] statement. BMJ. 2008-11-11 15:48:33 2008;337.~~
	~~# Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M: The PRECIS-2 tool: designing trials that are fit for purpose. BMJ 2015, 350:h2147~~
	----		----
	Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.		''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''

Lawrence at 16:52, 28 April 2025

2025-04-28T16:52:26Z

← Older revision		Revision as of 16:52, 28 April 2025
Line 49:		Line 49:
	# Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the [[CONSORT]] statement. BMJ. 2008-11-11 15:48:33 2008;337.		# Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the [[CONSORT]] statement. BMJ. 2008-11-11 15:48:33 2008;337.
	# Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M: The PRECIS-2 tool: designing trials that are fit for purpose. BMJ 2015, 350:h2147		# Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M: The PRECIS-2 tool: designing trials that are fit for purpose. BMJ 2015, 350:h2147
			----
			Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.

Lawrence at 16:50, 28 April 2025

2025-04-28T16:50:39Z

← Older revision		Revision as of 16:50, 28 April 2025
Line 24:		Line 24:

	==== Limited Use of Blinding ====		==== Limited Use of Blinding ====
	Blinding is generally limited in pragmatic trials. While explanatory RCTs may blind participants and clinicians to reduce bias, pRCTs often rely on objective outcomes and robust analytical methods to address potential biases, acknowledging that blinding may not always be practical.		[[Blinding]] is generally limited in pragmatic trials. While explanatory RCTs may blind participants and clinicians to reduce bias, pRCTs often rely on objective outcomes and robust analytical methods to address potential biases, acknowledging that blinding may not always be practical.

	==== Intention-to-Treat (ITT) Analysis ====		==== Intention-to-Treat (ITT) Analysis ====
	Analysis in pRCTs typically follows the intention-to-treat (ITT) principle, which includes all randomized participants in the final analysis, regardless of adherence to the assigned treatment. This reflects real-world practice, where non-adherence is common, and ensures that trial findings remain relevant to routine care settings.		[[Analysis]] in pRCTs typically follows the intention-to-treat (ITT) principle, which includes all randomized participants in the final analysis, regardless of adherence to the assigned treatment. This reflects real-world practice, where non-adherence is common, and ensures that trial findings remain relevant to routine care settings.

	=== Methodological Considerations ===		=== Methodological Considerations ===

	pRCTs exist along a continuum between fully explanatory and fully pragmatic designs. Tools such as the PRECIS-2 (Pragmatic-Explanatory Continuum Indicator Summary) framework help trialists evaluate the degree of pragmatism across key trial domains, including recruitment, intervention flexibility, and outcome selection. This allows researchers to align trial design with the study’s intended purpose.		pRCTs exist along a continuum between fully explanatory and fully pragmatic designs. Tools such as the [[PRECIS]]-2 (Pragmatic-Explanatory Continuum Indicator Summary) framework help trialists evaluate the degree of pragmatism across key trial domains, including recruitment, intervention flexibility, and outcome selection. This allows researchers to align trial design with the study’s intended purpose.

	From a regulatory and ethical perspective, pragmatic trials must balance the need for informed consent with the goal of minimizing disruption to care. Ethical frameworks should ensure that participants are protected while allowing sufficient flexibility for real-world implementation. Ethics review boards play an essential role in assessing the implications of broad eligibility and less intensive monitoring procedures.		From a regulatory and ethical perspective, pragmatic trials must balance the need for [[informed consent]] with the goal of minimizing disruption to care. Ethical frameworks should ensure that participants are protected while allowing sufficient flexibility for real-world implementation. [[Ethics]] review boards play an essential role in assessing the implications of broad eligibility and less intensive monitoring procedures.

	=== Implications for Healthcare and Policy ===		=== Implications for Healthcare and Policy ===
Line 42:		Line 42:

	Pragmatic RCTs bridge the gap between research and practice by emphasizing external validity and real-world applicability. By reflecting the complexities of routine healthcare delivery, pRCTs generate evidence that is both actionable and relevant to patients, providers, and policymakers. As healthcare systems seek to adopt interventions that are both effective and scalable, pRCTs will continue to play a pivotal role in guiding the future of evidence-based medicine.		Pragmatic RCTs bridge the gap between research and practice by emphasizing external validity and real-world applicability. By reflecting the complexities of routine healthcare delivery, pRCTs generate evidence that is both actionable and relevant to patients, providers, and policymakers. As healthcare systems seek to adopt interventions that are both effective and scalable, pRCTs will continue to play a pivotal role in guiding the future of evidence-based medicine.

			===Bibliography===

			# Thabane L, Kaczorowski J, Dolovich L, Chambers LW, Mbuagbaw L. Reducing the confusion and controversies around pragmatic trials: using the Cardiovascular Health Awareness Program (CHAP) trial as an illustrative example. Trials. 2015;16(1):387.
			# Sackett DL. Clinician-trialist rounds: 16. Mind your explanatory and pragmatic attitudes! - part 1:what? Clin Trials. 2013;10(3):495-498.
			# Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the [[CONSORT]] statement. BMJ. 2008-11-11 15:48:33 2008;337.
			# Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M: The PRECIS-2 tool: designing trials that are fit for purpose. BMJ 2015, 350:h2147

Lawrence: Created page with "== Pragmatic Randomized Controlled Trials (pRCTs) == Pragmatic randomized controlled trials (pRCTs) are designed to assess the effectiveness of interventions in real-world clinical settings. Unlike traditional explanatory RCTs, which test efficacy under tightly controlled conditions, pRCTs aim to reflect routine healthcare delivery by using broad inclusion criteria, flexible treatment protocols, and implementation strategies that mirror standard practice. This approach..."

2025-03-25T14:33:28Z

Created page with "== Pragmatic Randomized Controlled Trials (pRCTs) == Pragmatic randomized controlled trials (pRCTs) are designed to assess the effectiveness of interventions in real-world clinical settings. Unlike traditional explanatory RCTs, which test efficacy under tightly controlled conditions, pRCTs aim to reflect routine healthcare delivery by using broad inclusion criteria, flexible treatment protocols, and implementation strategies that mirror standard practice. This approach..."

New page

== Pragmatic Randomized Controlled Trials (pRCTs) ==

Pragmatic randomized controlled trials (pRCTs) are designed to assess the effectiveness of interventions in real-world clinical settings. Unlike traditional explanatory RCTs, which test efficacy under tightly controlled conditions, pRCTs aim to reflect routine healthcare delivery by using broad inclusion criteria, flexible treatment protocols, and implementation strategies that mirror standard practice. This approach prioritizes external validity and enhances the generalizability of findings, making pRCTs especially valuable for informing healthcare policy, clinical guidelines, and system-level decision-making.

=== Key Characteristics ===

==== Broad Inclusion Criteria ====
One of the defining features of pRCTs is their use of broad inclusion criteria. By minimizing exclusions, pRCTs ensure the study population is representative of typical patients seen in everyday clinical practice. This diversity enhances the applicability of findings across different healthcare settings.

==== Flexible Intervention Implementation ====
Intervention implementation in pRCTs is flexible, allowing healthcare providers to use clinical judgment rather than strictly adhering to standardized protocols. This design element accounts for real-world variation in care delivery and increases the relevance of trial findings.

==== Real-World Comparators ====
Pragmatic trials also tend to use real-world comparators. Rather than testing interventions against placebos or idealized controls, pRCTs usually compare new interventions to "usual care" or existing standard treatments. This makes the results more meaningful for clinicians and decision-makers.

==== Streamlined Recruitment and Consent ====
Recruitment and consent processes in pRCTs are designed to minimize disruption to routine care. Study recruitment may be embedded within clinical workflows, and some pRCTs employ opt-out or waived consent models, when ethically justified, to facilitate participation and reduce burden.

==== Clinically Relevant Outcomes ====
Outcome measures in pRCTs are clinically relevant and often patient-centered. Rather than relying on surrogate or mechanistic endpoints, these trials focus on outcomes such as hospitalizations, medication adherence, quality of life, and cost-effectiveness—metrics that matter to both patients and healthcare systems.

==== Minimal Data Collection Burden ====
To further ease integration with real-world care, pRCTs often utilize existing data sources such as electronic health records (EHRs), administrative claims, or disease registries. This reduces the need for additional study visits and data collection, improving feasibility and lowering trial costs.

==== Limited Use of Blinding ====
Blinding is generally limited in pragmatic trials. While explanatory RCTs may blind participants and clinicians to reduce bias, pRCTs often rely on objective outcomes and robust analytical methods to address potential biases, acknowledging that blinding may not always be practical.

==== Intention-to-Treat (ITT) Analysis ====
Analysis in pRCTs typically follows the intention-to-treat (ITT) principle, which includes all randomized participants in the final analysis, regardless of adherence to the assigned treatment. This reflects real-world practice, where non-adherence is common, and ensures that trial findings remain relevant to routine care settings.

=== Methodological Considerations ===

pRCTs exist along a continuum between fully explanatory and fully pragmatic designs. Tools such as the PRECIS-2 (Pragmatic-Explanatory Continuum Indicator Summary) framework help trialists evaluate the degree of pragmatism across key trial domains, including recruitment, intervention flexibility, and outcome selection. This allows researchers to align trial design with the study’s intended purpose.

From a regulatory and ethical perspective, pragmatic trials must balance the need for informed consent with the goal of minimizing disruption to care. Ethical frameworks should ensure that participants are protected while allowing sufficient flexibility for real-world implementation. Ethics review boards play an essential role in assessing the implications of broad eligibility and less intensive monitoring procedures.

=== Implications for Healthcare and Policy ===

Because pRCTs evaluate interventions as they would be applied in routine care, their findings carry direct relevance for clinical practice, policy formulation, and health system planning. They provide insight into how interventions perform across diverse populations, settings, and healthcare environments, thereby supporting evidence-based improvements and more efficient resource allocation.

=== Conclusion ===

Pragmatic RCTs bridge the gap between research and practice by emphasizing external validity and real-world applicability. By reflecting the complexities of routine healthcare delivery, pRCTs generate evidence that is both actionable and relevant to patients, providers, and policymakers. As healthcare systems seek to adopt interventions that are both effective and scalable, pRCTs will continue to play a pivotal role in guiding the future of evidence-based medicine.